Qiagen N.V. (QGEN)
NYSE • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Qiagen N.V. keeps $19 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 10 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Qiagen N.V. topped consensus on both adjusted EPS and revenue based on preliminary results for the second fiscal quarter of 2026 reported on Aug. 5, with adjusted EPS of $0.62 versus the $0.60 estimate and revenue of about $535.0 million versus $527.5 million, or roughly 4% and about 1% ahead, respectively. Revenue was roughly flat year over year, up 0.3% to about $535.0 million, while net income increased 7.4% to about $103.4 million from $96.2 million a year ago. Gross profit of about $338.0 million left gross margin at 63.2%, and operating income came to about $140.8 million with operating margin of 26.3%. Operating cash flow was about $200.7 million. Consensus for the next period calls for EPS of $0.63 on revenue of $551.3 million.
Next report — what to expect
Qiagen N.V. (QGEN) is set to report earnings on November 3, 2026. Wall Street is looking for EPS of $0.62 on revenue of $535.9 million. For trailing context, revenue rose +0.3% year over year last quarter. Qiagen has beaten EPS in 6 of its 8 most recent quarters.
About Qiagen N.V.
Qiagen N.V. (NYSE: QGEN) develops molecular testing and life-science tools for healthcare and research use, spanning diagnostic assays, laboratory consumables, instruments, and software. In FY2025, the company generated $2.1 billion in revenue. It serves the medical diagnostics and research market worldwide.
Today's Snapshot
QGEN ended the day slightly higher at 50.39, while its sector was weaker. Qiagen agreed to a takeover by EQT Private Equity, a private-equity buyer, worth about $12.1 billion including debt. QGEN is due to report earnings on 4 November.
Trading Volume
Below 10d avg (8.0M)
7.1M
vs S&P 500 Today
Outperforming Market
+0.86%
Updated: October 23, 2026 at 20:24 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$43.27 - $48.03Buy
- RSI (14)74.51Sell
- Stochastic %K (14, 3, 3)92.05Sell
- MACD Level (12, 26)1.55Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.